4',7-DihydroxyflavanoneCAS# 41680-09-5 |
- Liquiritigenin
Catalog No.:BCN5946
CAS No.:578-86-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 41680-09-5 | SDF | Download SDF |
| PubChem ID | 1889 | Appearance | Powder |
| Formula | C15H12O4 | M.Wt | 256.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | 69097-97-8;(+/-)-Liquiritigenin;DL-Liquiritigenin | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one | ||
| SMILES | C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC=C(C=C3)O | ||
| Standard InChIKey | FURUXTVZLHCCNA-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
4',7-Dihydroxyflavanone Dilution Calculator
4',7-Dihydroxyflavanone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.9017 mL | 19.5084 mL | 39.0168 mL | 78.0336 mL | 97.5419 mL |
| 5 mM | 0.7803 mL | 3.9017 mL | 7.8034 mL | 15.6067 mL | 19.5084 mL |
| 10 mM | 0.3902 mL | 1.9508 mL | 3.9017 mL | 7.8034 mL | 9.7542 mL |
| 50 mM | 0.078 mL | 0.3902 mL | 0.7803 mL | 1.5607 mL | 1.9508 mL |
| 100 mM | 0.039 mL | 0.1951 mL | 0.3902 mL | 0.7803 mL | 0.9754 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2H-1-Benzopyran-7-yloxy
Catalog No.:BCN3580
CAS No.:41680-08-4
- Catharanthine hemitartrate
Catalog No.:BCN8463
CAS No.:4168-17-6
- 7-O-Methyl morroniside
Catalog No.:BCN3882
CAS No.:41679-97-4
- Koaburaside
Catalog No.:BCN5475
CAS No.:41653-73-0
- Lacinilene C
Catalog No.:BCN5474
CAS No.:41653-72-9
- Ciclopirox ethanolamine
Catalog No.:BCC4372
CAS No.:41621-49-2
- Ylangenol
Catalog No.:BCN6705
CAS No.:41610-69-9
- (-)-Pinoresinol 4-O-glucoside
Catalog No.:BCN7251
CAS No.:41607-20-9
- 4,R-ajmalicine N-oxide
Catalog No.:BCN5473
CAS No.:41590-29-8
- Carboplatin
Catalog No.:BCC1170
CAS No.:41575-94-4
- Poricoic acid G
Catalog No.:BCN8267
CAS No.:415724-84-4
- RI-1
Catalog No.:BCC1896
CAS No.:415713-60-9
- 8-Methyleugenitol
Catalog No.:BCN6459
CAS No.:41682-21-7
- Arctigenin 4'-O-beta-gentiobioside
Catalog No.:BCN2847
CAS No.:41682-24-0
- 8-Acetoxypentadeca-1,9Z-diene-4,6-diyn-3-ol
Catalog No.:BCN1444
CAS No.:41682-30-8
- Epiaschantin
Catalog No.:BCN7206
CAS No.:41689-50-3
- Epimagnolin A
Catalog No.:BCN7831
CAS No.:41689-51-4
- Indicine N-oxide
Catalog No.:BCN1996
CAS No.:41708-76-3
- Croalbidine
Catalog No.:BCN2068
CAS No.:41714-30-1
- Bavachromene
Catalog No.:BCN3191
CAS No.:41743-38-8
- Procyanidin A2
Catalog No.:BCN6805
CAS No.:41743-41-3
- Luteone
Catalog No.:BCN5476
CAS No.:41743-56-0
- Sugeroside
Catalog No.:BCN6961
CAS No.:41743-57-1
- Pyrochamissanthin
Catalog No.:BCN3612
CAS No.:41743-60-6
Liquiritigenin and liquiritin alleviated MCT-induced HSOS by activating Nrf2 antioxidative defense system.[Pubmed:29908794]
Toxicol Appl Pharmacol. 2018 Sep 15;355:18-27.
Hepatic sinusoidal obstruction syndrome (HSOS) is a serious and life-threatening liver disease. Liquiritigenin (LG) and liquiritin (LQ) are natural flavonoids distributed in Glycyrrhizae Radix et Rhizoma (Gan-cao). This study aims to investigate the protective effect and mechanism of LG and LQ against monocrotaline (MCT)-induced HSOS. Results of serum alanine/aspartate aminotransferases (ALT/AST) activities, liver histological evaluation and scanning electron microscope observation, and hepatic metalloproteinase-9 (MMP-9) expression demonstrated that LG and LQ both alleviated HSOS induced by MCT in rats. Results of hepatic reactive oxygen species (ROS), malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), oxidized glutathione (GSSG) and reduced glutathione (GSH) contents, glutathione reductase (GR) and superoxide dismutase (SOD) activities showed that LG and LQ attenuated MCT-induced liver oxidative stress injury. Furthermore, LG and LQ were found to promote Nrf2 nuclear translocation and lead to the increased expression of Nrf2 downstream antioxidative genes. Molecule docking analysis indicated the potential interaction of LG and LQ with Nrf2 binding site in the kelch-like ECH-associated protein-1 (Keap1) protein. Finally, Nrf2 knock-out mice were used. The results showed that LG and LQ both alleviated MCT-induced HSOS in wild-type mice, but such protection was totally diminished in Nrf2 knock-out mice. In conclusion, our study revealed that LG and LQ alleviated MCT-induced HSOS by inducing the activation of hepatic Nrf2 antioxidative defense system.
